[go: up one dir, main page]

RU98101105A - NEW APPLICATION FOR MEDICAL PURPOSES - Google Patents

NEW APPLICATION FOR MEDICAL PURPOSES

Info

Publication number
RU98101105A
RU98101105A RU98101105/14A RU98101105A RU98101105A RU 98101105 A RU98101105 A RU 98101105A RU 98101105/14 A RU98101105/14 A RU 98101105/14A RU 98101105 A RU98101105 A RU 98101105A RU 98101105 A RU98101105 A RU 98101105A
Authority
RU
Russia
Prior art keywords
compound
formula
dyspepsia
paragraphs
symptoms
Prior art date
Application number
RU98101105/14A
Other languages
Russian (ru)
Other versions
RU2209064C2 (en
Inventor
Ларс Фендрикс
Андерс Петтерсон
Original Assignee
Астра Актиеболаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502219A external-priority patent/SE9502219D0/en
Application filed by Астра Актиеболаг filed Critical Астра Актиеболаг
Publication of RU98101105A publication Critical patent/RU98101105A/en
Application granted granted Critical
Publication of RU2209064C2 publication Critical patent/RU2209064C2/en

Links

Claims (10)

1. Применение соединения общей формулы I
Figure 00000001

в которой А представляет собой:
Figure 00000002

Figure 00000003

Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

Figure 00000008

Figure 00000009

Figure 00000010

Figure 00000011

Figure 00000012

Figure 00000013

Figure 00000014

или его физиологически приемлемой соли и/или стереохимического изомера для производства медикамента, обладающего действием на симптомы диспепсии.1. The use of compounds of General formula I
Figure 00000001

in which a represents:
Figure 00000002

Figure 00000003

Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

Figure 00000008

Figure 00000009

Figure 00000010

Figure 00000011

Figure 00000012

Figure 00000013

Figure 00000014

or its physiologically acceptable salt and / or stereochemical isomer for the manufacture of a medicament having an effect on the symptoms of dyspepsia. 2. Применение по п. 1 соединения формулы I, в которой А представляет собой I:1. 2. The use according to claim 1 of a compound of formula I, in which A represents I: 1. 3. Применение по п. 1 соединения формулы I, в которой А представляет собой I:5. 3. The use according to claim 1 of a compound of formula I, in which A represents I: 5. 4. Фармацевтический препарат для применения при профилактике и/или лечении симптомов диспепсии, в котором активным ингредиентом является соединение по п. 1. 4. A pharmaceutical preparation for use in the prophylaxis and / or treatment of symptoms of dyspepsia, in which the active ingredient is a compound according to claim 1. 5. Фармацевтический препарат по п. 4 в форме стандартной дозы. 5. The pharmaceutical preparation according to claim 4 in the form of a standard dose. 6. Фармацевтический препарат по пп. 4 и 5, содержащий активные ингредиенты в сочетании с фармацевтически приемлемым носителем. 6. The pharmaceutical product according to paragraphs. 4 and 5, containing the active ingredients in combination with a pharmaceutically acceptable carrier. 7. Фармацевтический препарат по пп. 4-6, содержащий в качестве активных ингредиентов соединение формулы I, в которой А представляет собой I:1. 7. The pharmaceutical product according to paragraphs. 4-6, containing as active ingredients a compound of formula I, in which a represents I: 1. 8. Фармацевтический препарат по пп. 4-6, содержащий в качестве активных ингредиентов соединение формулы I, в которой А представляет собой I:5. 8. The pharmaceutical preparation according to paragraphs. 4-6, containing as active ingredients a compound of formula I, in which a represents I: 5. 9. Способ профилактики и лечения симптомов диспепсии у млекопитающих, включая человека, при котором эффективным количеством соединения по п. 1 воздействуют на хозяина, нуждающегося в такой профилактике и лечении. 9. A method for the prevention and treatment of symptoms of dyspepsia in mammals, including humans, in which an effective amount of a compound according to claim 1 acts on a host in need of such prevention and treatment. 10. Способ по п. 9, отличающийся тем, что воздействуют соединением формулы I, в которой А представляет собой I:1 или I:5. 10. The method according to p. 9, characterized in that it is affected by a compound of formula I, in which A represents I: 1 or I: 5.
RU98101105/14A 1995-06-19 1996-06-10 New application in medicinal purposes RU2209064C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502219A SE9502219D0 (en) 1995-06-19 1995-06-19 Novel medical use
SE9502219.0 1995-06-19

Publications (2)

Publication Number Publication Date
RU98101105A true RU98101105A (en) 1999-12-10
RU2209064C2 RU2209064C2 (en) 2003-07-27

Family

ID=20398663

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98101105/14A RU2209064C2 (en) 1995-06-19 1996-06-10 New application in medicinal purposes

Country Status (27)

Country Link
US (1) US6096772A (en)
EP (1) EP0840607B1 (en)
JP (1) JPH11507921A (en)
KR (1) KR19990023021A (en)
CN (1) CN1091595C (en)
AT (1) ATE214925T1 (en)
AU (1) AU706660B2 (en)
BR (1) BR9608472A (en)
CA (1) CA2225175A1 (en)
CZ (1) CZ289400B6 (en)
DE (1) DE69620186T2 (en)
DK (1) DK0840607T3 (en)
EE (1) EE03385B1 (en)
ES (1) ES2173294T3 (en)
HU (1) HUP9901448A3 (en)
IL (1) IL122659A (en)
IS (1) IS4619A (en)
MY (1) MY114716A (en)
NO (1) NO975922L (en)
NZ (1) NZ310606A (en)
PT (1) PT840607E (en)
RU (1) RU2209064C2 (en)
SE (1) SE9502219D0 (en)
SK (1) SK172197A3 (en)
UA (1) UA55387C2 (en)
WO (1) WO1997000070A1 (en)
ZA (1) ZA964690B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277112B1 (en) 1996-07-16 2001-08-21 Arthrocare Corporation Methods for electrosurgical spine surgery
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6602248B1 (en) 1995-06-07 2003-08-05 Arthro Care Corp. Methods for repairing damaged intervertebral discs
US7393351B2 (en) 1995-06-07 2008-07-01 Arthrocare Corporation Apparatus and methods for treating cervical inter-vertebral discs
US20050004634A1 (en) 1995-06-07 2005-01-06 Arthrocare Corporation Methods for electrosurgical treatment of spinal tissue
US7357798B2 (en) 1996-07-16 2008-04-15 Arthrocare Corporation Systems and methods for electrosurgical prevention of disc herniations
US6726684B1 (en) 1996-07-16 2004-04-27 Arthrocare Corporation Methods for electrosurgical spine surgery
SE9800550D0 (en) * 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
US20030158545A1 (en) 2000-09-28 2003-08-21 Arthrocare Corporation Methods and apparatus for treating back pain
BR0102252B1 (en) * 2001-04-10 2013-10-22 Angiotensin II AT1 Receptor Antagonist Controlled Release System, Pharmaceutical Composition and Use
AU2002362310A1 (en) 2001-09-14 2003-04-01 Arthrocare Corporation Methods and apparatus for treating intervertebral discs
US7413751B2 (en) * 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
DE602004029982D1 (en) * 2003-01-30 2010-12-23 Lek Pharmaceuticals PREPARATION OF A NEW PHARMACEUTOLIZED LOSARTANE SALT AND ITS FORMS THROUGH NEW CLEANING AND INSULATION METHODS
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US8979838B2 (en) 2010-05-24 2015-03-17 Arthrocare Corporation Symmetric switching electrode method and related system
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2263635A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substitiuted triazoles as neurotensin antagonists
GB2263637A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
GB2263638A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists
US5250558A (en) * 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB2263639A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
DE4203872A1 (en) * 1992-02-11 1993-08-12 Thomae Gmbh Dr K IMIDAZO (1,2-A) PYRIDINES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD OF PREPARING THEM
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Similar Documents

Publication Publication Date Title
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
RU95102778A (en) Use of 2-phenyl-3-aroylbenzothiophenes for osseous tissue loss inhibition and serum cholesterol level decrease, pharmaceutical preparation containing 2-phenyl-3-aroylbenzothiophene
RU94041223A (en) Agent for motoneuron disease treatment
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
RU94046316A (en) Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment
RU93051780A (en) CONTROLLED RELEASE COMPOSITIONS CONTAINING OXYCODONE, METHOD FOR REDUCING DAILY DOSES OF PRODUCTS CONTAINING OXYCODON
RU2209064C2 (en) New application in medicinal purposes
RU2003118411A (en) 1-Methylcarbapenem Crystal Derivatives
RU94045866A (en) Use of bis-phenylalkylpiperazines for treatment of disorders caused by substance abuse, method of treatment
TR199701497T1 (en) Composition that prevents brain disease.
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
RU98103388A (en) (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION
RU97120700A (en) NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR
FR2500303B1 (en)
AU4519189A (en) Medicaments for the treatment of toxoplasmosis
AU4519289A (en) Medicament for the treatment of cryptosporidiosis
KR970061084A (en) How to promote chicken development
RU94045140A (en) Pharmaceutical composition for prophylaxis and treatment of viral diseases, method of its preparing and use of bradykinin antagonist or its physiologically tolerant salt as agent for prophylaxis and treatment of viral diseases
US3686409A (en) Combination of l-dopa and 2-imino-5-phenyl-4-oxazolidinone used to treat parkinson{40 s disease
GEP19970834B (en) 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
RU92016559A (en) DIALCOXY-PYRIDINYLBENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING OR TREATMENT, METHOD FOR PRODUCING THEM, USE AND INTERMEDIATE COMPOUNDS
KR910018026A (en) Drugs for treating urination disorders containing α-phenyl-αpyridylalkanoic acid derivatives
RU95119823A (en) APPLICATION OF THE DIETHYLAMINE SALT OF CERULETIDE FOR THE TREATMENT OF PSORIASIS
RU95109687A (en) SUBSTITUTED KURURENINES, METHOD OF THEIR PRODUCTION, USE AS A MEDICINE PREPARATION, PHARMACEUTICAL COMPOSITION
RU93058599A (en) NEW DIMETHYLAMINE-OXYALCANDIPHOSPHONIC ACIDS AND THEIR SALTS, METHOD FOR PRODUCING THERE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS, APPLICATION